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Abstract
It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the po-
tential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene
therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined
the antiarrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models.
Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemaggluti-
nating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the
myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF)was induced
by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF
gene therapy ( p< 0.01). Histological analyses revealed that the number of vessels in the ischemic
border zone was greatly increased after HGF gene injection. These findings revealed that HGF
gene therapy has an anti-arrhythmic effect after myocardial ischemia.
KEYWORDS: ventricular arrhythmia, HGF (hepatocyte growth factor), ischemia, HVJ (hemag-
glutinating virus of Japan)
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It was recently reported that gene therapy using hepatocyte growth factor(HGF)has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-
arrhythmic eﬀect of HGF gene therapy in rat acute and old myocardial infarction models.
Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagg-
lutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular ﬁbrillation(VF)was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy( ＜0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These ﬁndings revealed that HGF gene therapy has an anti-arrhythmic eﬀect after myocardial ischemia.
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T he mortality rates of patients with coronary artery disease of new or recurrent myocardial infarction
(MI) are high. Various strategies, including medical treatment and revascularization therapy to limit residual ischemia, have been used to try to reduce the clinical consequences of the loss of cardiac muscle mass.
Intramyocardial gene therapy using genes encoding angiogenic cytokines has been proposed as an alternative strategy for treating coronary artery disease of new or
 
recurrent MI［1, 2］. This strategy is designed to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries to prevent cardiac is-
chemia and to potentially restore myocardial function. It has also been reported that basic ﬁbroblast growth factor
(b-FGF)or vascular endothelial growth factor (VEGF)
gene transfer may have a favorable eﬀect on the recovery of myocardial ischemia in humans［3］, and there are indications that this may be associated with an increase in myocardial performance［4, 5］.
Hepatocyte growth factor(HGF)has also been pos-
tulated to be a potent angiogenic growth factor, since it is
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a mitogen for various endothelial cells［6, 7］and is also a potent inducer of tube formation. HGF gene therapy can induce angiogenesis and reduce the infarct size after myocardial ischemia［8, 9］.
The existence of malignant ventricular arrhythmia
(ventricular ﬁbrillation or ventricular tachycardia) is an important factor in addition to left ventricular dysfunction for predicting prognosis after myocardial infarction［10-
12］. However, the relationship between angiogenesis induced by HGF gene transfection and the inhibition of ventricular arrhythmia has not been elucidated. We hypothesized that angiogenesis induced by HGF gene transfection can reduce ventricular vulnerability in animals with acute myocardial infarction, and the ventricular ﬁbrillation duration time in animals with old myocardial infarction.
The aim of this study, therefore,was to determine the eﬀects of the direct injection of the HGF gene on the inhibition of ventricular arrhythmias in acute or chronic myocardial ischemia.
Materials and Methods
 
All animal experiments were carried out in accordance with the Guidelines for Animal Experiments at Okayama University Medical School, Japanese Government Ani-
mal Protection and Management Law(No. 105)and the Japanese Government Notiﬁcation on the Feeding and Safekeeping of Animals(No. 6). All eﬀorts were made to minimize animal suﬀering.
To produce a HGF expression vector, human HGF cDNA(2.2 kb)was inserted into the EcoRI and NotI sites of the pUC-SRαexpression of the vector plasmid. In this plasmid, the transcription of HGF cDNA was under the control of the SRαpromoter.
We previously reported a high eﬃcacy of transfection with HVJ-coated liposomes［13］. Brieﬂy, phosphatidyl-
serine, phosphatidylchorine, and cholesterol were mixed at a weight ratio of 1:4.8:2 in tetrahydrofuran. The lipid mixture(10 mg)was deposited on the sides of a ﬂask by removal of the solvent in a rotary evaporator. The high mobility group(HMG)-1 puriﬁed from calf thymus was mixed with plasmid DNA(300μg)in a 200μl balanced salt solution(BSS;133 mM NaCL, 5.4 mM KCL, 10 mM Tris-HCL, pH 7.6)at 20°C for 1 h, and then the mixture was added to the dried lipid. The liposome-DNA-
HMG 1 complex suspension was mixed by vortex,
sonication for 3 sec, and shaking for 30 min. Puriﬁed HVJ (Z strain)was inactivated by UV irradiation (110 erg/mm?/s) for 3 min immediately before use. The liposome suspension(0.5 ml, containing 10 mg lipid)was mixed with HVJ(20000 hemagglutinating units)in a total volume of 4 ml BSS. The mixture was incubated for 10 min at 4°C and then for 30 min with gentle shaking at 37
°C. Free HVJ was removed from the HVJ-liposome by sucrose density gradient centrifugation. The top layer of the sucrose gradient containing the HVJ-liposome-DNA complex was collected and used immediately.
The HVJ-liposome complex was injected into the rats’
hearts using the method reported previously［13］.
Brieﬂy, HVJ-liposome complex containing the human HGF gene or a control vector (100 ng/10μl in each liposome)was injected directly into the apex of each rat’s heart with a 27 G needle.
The antiarrhythmic eﬀects were evaluated by measurement of the ventricular ﬁbrillation duration time in the old MI model and the ventricular ﬁbrillation threshold (VFT) in an acute MI model.
Twenty male Wistar rats (weighing 200-300 g)were divided into an HGF vector transfected (MI＋HGF)
group (n＝10)and an empty vector transfected (MI＋
Cont)group(n＝10). The rats were anesthetized with an intraperitoneal injection of sodium pentobarbital(50 mg/
kg). The animals were intubated, and ventilation was performed with room air (1.2 ml/100 g, 65 bpm). The heart of each animal was quickly exteriorized through a left lateral thoracotomy. The left anterior descending artery(LAD)was ligated 3 mm from the aortic root.
Immediately after ligation, 10μl HVJ-liposome complex was injected into the apex of the myocardium in a non-infarcted area using the method described previously
［13］. Then the thorax was enclosed by the layer method,
and a catheter was cannulated to prevent pneumothorax.
Fourteen days after surgery, the rats were anesthet-
ized again with an intraperitoneal injection of urethane(1.1 mg/kg). A lead II surface electrocardiogram(ECG)was recorded. The rats were intubated and connected to a ventilator. After mediasternal thoracotomy, 2 needle electrodes were placed on the right ventricular (RV)
epicardial surface outside the margin of the infarct area with a distance of 3 mm between the electrodes. The hearts were stimulated with rectangular pulses at a fre-
quency of 25 Hz, impulse length of 8 ms and stimulation
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duration of 500 ms with a current intensity of 10 mA.
The duration of ventricular ﬁbrillation(VF)was measured in an ECG.
Thirty male Wistar rats (weighing 200-300 g)were divided into three groups:a non-infarcted myocardium transfected empty vector (Sham) group (n＝10), an infarcted myocardium transfected empty vector (Cont＋
MI)group(n＝10), and an infarcted myocardium trans-
fected HGF vector (HGF＋MI) group (n＝10). The animals were anesthetized with an intraperitoneal injection of sodium pentobarbital(50 mg/kg). The animals were then intubated and connected to a ventilator. The heart of each animal was quickly exteriorized through a left lateral thoracotomy. Ten μl of HVJ-liposome complex was injected into the apex of the myocardium using a method described previously. The thorax was enclosed by the layer method, and a catheter was cannulated to prevent pneumothorax.
Fourteen days after the injection of the HVJ-liposome complex into the non-infarcted myocardium, the rats were anesthetized again with an intraperitoneal injection of urethane(1.1 g/kg). The rats were ventilated with room air using a respirator, and the ECG was recorded. In the HGF＋MI and Cont＋MI groups, LAD was ligated for 30 min after mediasternal thoracotomy, and reperfusion was performed for 3 h. In the Sham group, only
 
mediasternal thoracotomy was performed. Two needle electrodes were placed on the RV free wall outside the infarcted area. VF was induced by a.c. stimulation using a previously reported method［14］that was modiﬁed on the basis of the results of the preliminary experiments in the control and infarcted rats(n＝30). Brieﬂy, the hearts were stimulated with rectangular pulses at a frequency of 25 Hz, impulse length of 8 ms, and stimulation duration of 500 ms. The current intensity was increased in incre-
ments of 0.1 mA until VF was attained. Two minutes after stabilization, another stimulus was given with the same current intensity. The ventricular ﬁbrillation thresh-
old(VFT)was determined as the lowest current intensity at which two consecutive stimuli precipitated VF.
Hematoxylin and eosin
(HE)staining was performed to assess the angiogenesis of the vessels in the Cont＋HGF and MI＋HGF groups.
The hearts were arrested with potassium chloride,
removed, and rinsed in saline solution. After dissection of the atria and great vessels, the heart weights were determined. Transverse sections of each heart at 2 mm intervals between the left ventricular base to the apex were obtained. The specimens were ﬁxed in 10 formalin and embedded in paraﬃn. Transverse sections were subse-
quently stained with HE in a standard manner. Slides were observed with a Zeiss Axioskop 2 plus light microscope equipped with a polarized set and analyzed with Studio Lite software.
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Fig.1  Electrocardiogram of the old infarction model.
MI＋cont, empty vector transfected group. MI＋HGF, HGF vector transfected group. The VF in a representative case in the MI＋HGF group is shorter than that in the MI group.
Fig.2  Ventricular ﬁbrillation duration in OMI model.
VF duration was reduced when the HGF gene was induced. Data are given as means±S.E.M.
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The tubular-shaped small vessels(diameter＜100μm)
were counted under light microscopy (magniﬁcation,×
100)in a blind manner. The total number of vessels in each section was summed and expressed as the number of vessels per section. At least 8 sections for each heart were examined. Areas in which angiogenesis was quantiﬁed in the injected site and around the injected site were randomly selected.
All values are expressed as means±
SEM. Statistical analysis of variance with paired Student’s t test was used to determine signiﬁcant diﬀerences in the VF durations and numbers of vessels.
Fisher’s protected least signiﬁcant diﬀerence test was used for comparison of the VFTs. Statistical signiﬁcance was deﬁned as P＜0.05.
Results
 
To examine the arrythmogenecity of HGF gene induction,
we ﬁrst measured ventricular ﬁbrillation duration in the old myocardial infarction model. A current intensity of 10 mA was suﬃcient to induce ventricular arrhythmia. VF was inducible by any programmed stimulations, but was not sustained, and terminated spontaneously in all hearts.
The VF duration was signiﬁcantly reduced in the HGF vector transfected (MI＋HGF) group (1.0±0.27 sec)
compared to that in the empty vector transfected(MI＋
Cont)group(3.7±0.90 sec)(P＜0.01)(Fig. 1, Fig. 2).
The acute myocardial infarction model was used to evalu-
ate VFT. In all rats, VF was precipitated by program-
med stimulation until the current intensity reached 10 mA.
VFT was lower in the MI group(0.63±0.17 mA)than in the Sham group (3.4±0.52 mA) (P＜0.01) and HGF＋MI group(3.8±0.49 mA)(P＜0.01)(Fig. 3).
The angiogenesis was enhanced in the border zone around the infarcted myocar-
dium in the MI＋HGF group(Fig. 4). The number of
 
Fig.4  Hematoxylin and eosin staining in the OMI model. Bar indicate 50μm.
Fig.3  Ventricular ﬁbrillation threshold in the AMI model.
VFT was decreased after coronary ligation when the HGF gene was not injected. In the MI＋HGF group, VFT was signiﬁcantly increased.
Data are given as means±S.E.M.
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Recently, several new strategies, including gene ther-
apy and cellular transplantation, have been successful in reducing the clinical consequences of the loss of cardiac muscle mass after myocardial ischemia［8］. However,
the feasibility and safety of these new methods have not yet been determined. Some studies using autologous skeletal myoblast transplantation in patients with severe ischemic cardiomyopathy suggested an arrhythmogenic potential in such patients［15］. Actually, it has been reported that the existence of arrhythmic events, espe-
cially ventricular ﬁbrillation/tachycardia associated with ventricular remodeling, is a major factor in determining the mortality after myocardial infarction［12］. Therefore,
it is important to evaluate the arrhythmogenic potential before starting a human trial.
Intramyocardial gene delivery using genes encoding angiogenic cytokines has been proposed as a strategy for patients with ischemic heart disease to promote the development of supplemental collateral vessels around the occluded native arteries in order to prevent cardiac is-
chemia and to restore cardiac function［5, 8, 9］. We previously reported that HGF gene delivery using the HVJ-liposome method has a favorable eﬀect on the recovery of myocardial ischemia in animal models of myocardial ischemia［13］. The present study was carried
 
out to determine whether this gene therapy prevents or increases arrhythmic events after myocardial ischemia.
We found that the duration of induced VF after chronic ischemia was signiﬁcantly decreased in the MI＋
HGF group. Similar results were obtained using the VF threshold after acute ischemia in the HGF＋MI group.
The present study showed a marked fall in the VFT after coronary artery ligation, which agrees with the results of an earlier study［16］. Similar methods have been applied before［17, 18］. We cannot completely explain the mechanism of these results, but these favorable outcomes may lead to improvement in the survival rate after HGF gene therapy. It is known that infarcted myocardial volume can be reduced by means of HGF gene induction
［19］. In the present study, the number of vessels was increased after HGF gene transfection. This angiogenesis eﬀect might reduce the ischemic myocardial volume after myocardial infarction and lead to reduction of the arrhyth-
mic property of the HGF gene-transfected myocardium.
We previously reported that HGF gene delivery using the HVJ-liposome method has a favorable eﬀect on the recovery of myocardial ischemia in animal models of myocardial ischemia by means of pleiotropic eﬀects on various cells［6］. Ueda et al.reported that the c-Met/
HGF receptor is expressed in cardiomyocytes, and that HGF prevents myocyte death due to oxidative stress
［20］. Nakamura et al. also reported that HGF gene transfection before myocardial ischemia attenuates reper-
fusion injury after releasing the coronary artery［9］.
Taniyama et al. reported that local HGF expression is involved in the prevention of myocardial injury by an-
giotensin II blockade through its antiﬁbrotic action［21］.
In this study, we observed a large increase in the number of vessels in the border zone of ischemia. We speculate that this eﬀect reduces ﬁbrosis and is related to the negative remodeling after myocardial ischemia. It is known that infarct size can be reduced by means of HGF gene induction［19］. However, we did not measure the infarcted myocardial volume in the present study. Further investigation is needed to determine whether the infarcted myocardium volume after HGF gene transfection is associated with an arrhythmic response. It would also be interesting to include a Sham＋HGF group in a VFT experiment in order to evaluate the arrhythmogenic response of HGF gene therapy.
In conclusion, HGF gene therapy has a favorable anti-arrhythmic eﬀect after acute or chronic myocardial ischemia. Although further study is needed to determine
 
Fig.5  Number of vessels.
The number of small vessels increased when the HGF vector was transfected. Data are given as means±S.E.M.
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the mechanism by which this occurs, it has been shown that HGF gene therapy could be a safe treatment after myocardial ischemia.
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